Those technologies may be unavailable for licensing or only available on onerous terms. If the technology owner seeks its maximum value, the cost of technology acquisition can become prohibitive and its recovery in the market almost impossible. Companies may be required to use their own patented technologies as trading chips to get access to third-party technology. The more such chips you have, the more chances you have of obtaining freedom to operate. Therefore, companies that started early in biotechnology and have a broad technology portfolio are at an advantage.
Some technologies still have to be tried, tested and mastered.
The learning curve this requires can be longer than anticipated. Some people predict that the changes taking place are just the beginning and that there is more to come in the next three to five years. These changes will provide opportunities for some companies, and nightmares for others. As the process continues, we can expect many casualties, some survivors, and a few successes. B-9000 Gent, Belgium.